The AstraZeneca plc (AZN) Lifted to “Hold” at Shore Capital

The AstraZeneca plc (AZN) Lifted to “Hold” at Shore Capital

AZN has been the topic of a number of other research reports. Goldman Sachs Group Inc decreased their price target on shares of AstraZeneca plc from GBX 4,000 ($51.38) to GBX 3,900 ($50.10) and set a sell rating on the stock in a research note on Tuesday, January 24th. Investec started coverage on shares of AstraZeneca plc in a research note on Monday, January 23rd. They issued a hold rating and a GBX 4,600 ($59.09) price target on the stock. HSBC Holdings plc reiterated a hold rating and issued a GBX 4,700 ($60.37) price target on shares of AstraZeneca plc in a research note on Wednesday, January 25th. Beaufort Securities restated a hold rating on shares of AstraZeneca plc in a research report on Wednesday, January 18th. Finally, Jefferies Group LLC increased their target price on shares of AstraZeneca plc from GBX 5,250 ($67.44) to GBX 5,350 ($68.72) and gave the stock a buy rating in a research report on Thursday, March 9th. Six investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of Hold and an average price target of GBX 5,026.80 ($64.57).

Shore Capital upgraded shares of AstraZeneca plc (LON:AZN) to a hold rating in a report published on Tuesday, May 16th. They currently have GBX 4,800 ($61.66) target price on the biopharmaceutical company’s stock.

Shares of AstraZeneca plc (LON AZN) opened at 5356.00 on Tuesday. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The firm’s 50-day moving average price is GBX 4,912.60 and its 200-day moving average price is GBX 4,614.19. The stock’s market cap is GBX 67.81 billion. AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:AZN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment